ABIMPROSYC SPORT has been developed for individuals exposed to high physical demand, repeated training loads, and metabolic stress associated with performance environments. The formulation focuses on post-exertion recovery, neurometabolic balance, and redox stabilization, without the use of stimulants or compounds that alter cardiovascular dynamics.

Its design follows a triphasic adaptive format, integrating complementary delivery systems that support physiological restoration during both active and recovery phases.

Optimized Functional Core

The formula integrates multiple functional axes relevant to sports physiology:

Mitochondrial fatty acid transport support, facilitating efficient substrate utilization during recovery phases.

Buffered sports-grade amino acids, aimed at supporting structural repair and neuromuscular stability.

HPA axis modulators, combined with endogenous GABA-supportive compounds to favor adaptive stress response and nervous system regulation.

Post-exertion structural antioxidants, designed to mitigate exercise-induced oxidative stress and support cellular redox balance.

Biorhythmic release compounds, intended to promote nighttime physiological repair and circadian synchronization.

Each daily dose incorporates three complementary delivery systems:

Liposomal capsule for enhanced bioavailability of key actives

Functional vegetable capsule containing structural nutrients and metabolic cofactors

Sublingual tablet designed for rapid neuromodulatory signaling support

This configuration is implemented within an AM/PM regimen, allowing metabolic activation during the day and recovery-focused support during the nocturnal phase.

Functional Validation and Regulatory Support

All ingredients used in the ABIMPROSYC SPORT formulation comply with internationally recognized safety frameworks:

Classified under GRAS (21 CFR §170.30), Novel Food, and/or Natural Health Product (NHP) regulatory categories.

Daily amounts remain within established safety thresholds, avoiding pharmacodynamic conflicts or interactions with medications.

Preclinical ex vivo functional models have demonstrated:

Reduction of pro-inflammatory cytokines IL-6 and TNF-α

Increase of anti-inflammatory IL-10

Decrease in reactive oxygen species (ROS) levels

Maintenance of cellular viability in models such as A375, PANC-1, and THP-1

These findings support the formulation’s intended role in post-load physiological recovery, inflammatory balance, and redox resilience in performance-oriented environments.

#nutraceuticos #salud #bienestar #mexico #latinoamerica